Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Liver Diseases |
Free Subscription
1 Am J Gastroenterol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Liver Diseases is free of charge.
How I Approach It: Prompt Engineering for Generative Artificial Intelligence
(GAI) in Gastroenterology and Hepatology.
Am J Gastroenterol. 2024 Jan 31. doi: 10.14309/ajg.0000000000002689.
PubMed
Surgical Treatment and Outcome of Ovarian Cancer Patients With Liver Metastases:
Experience of a Tertiary Hepatic and Peritoneal Surface Malignancy Center.
Anticancer Res. 2024;44:731-741.
PubMed
Abstract available
Identification of FOXP1 as a favorable prognostic biomarker and tumor suppressor
in intrahepatic cholangiocarcinoma.
BMC Cancer. 2024;24:137.
PubMed
Abstract available
iCare - a self-directed, interactive online program to improve health and
wellbeing for people living with upper gastrointestinal or
hepato-pancreato-biliary cancers, and their informal carers: the study protocol
for a Phase II randomised controlled t
BMC Cancer. 2024;24:144.
PubMed
Abstract available
Prognostic role of macrophages and mast cells in the microenvironment of
hepatocellular carcinoma after resection.
BMC Cancer. 2024;24:142.
PubMed
Abstract available
Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the
importance of LDHD in the prognosis of hepatocellular carcinoma patients.
BMC Cancer. 2024;24:156.
PubMed
Abstract available
G6PD and machine learning algorithms as prognostic and diagnostic indicators of
liver hepatocellular carcinoma.
BMC Cancer. 2024;24:157.
PubMed
Abstract available
Dietary intervention reverses molecular markers of hepatocellular senescence in
the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
BMC Gastroenterol. 2024;24:59.
PubMed
Abstract available
Identification of differentially methylated regions associated with both liver
fibrosis and hepatocellular carcinoma.
BMC Gastroenterol. 2024;24:57.
PubMed
Abstract available
Efficacy and safety of the combination of camrelizumab and apatinib in the
treatment of liver cancer: a systematic review and single-arm meta-analysis.
BMC Gastroenterol. 2024;24:55.
PubMed
Abstract available
Pediatric cancer incidence among individuals with overgrowth syndromes and
overgrowth features: A population-based assessment in seven million children.
Cancer. 2024;130:467-475.
PubMed
Abstract available
Hepatocellular carcinoma, vascular endothelial growth factor receptors-targeting
agents, and hypertension: A much more complicated relationship than expected.
Cancer. 2024 Jan 27. doi: 10.1002/cncr.35218.
PubMed
Treatment of Hepatocellular Carcinoma in the Elderly: Slash or Burn?
Dig Dis Sci. 2024 Feb 1. doi: 10.1007/s10620-023-08247.
PubMed
Comparison of Surgical Resection and Radiofrequency Ablation in Elderly Patients
with Hepatocellular Carcinoma.
Dig Dis Sci. 2024 Feb 1. doi: 10.1007/s10620-023-08245.
PubMed
Abstract available
Fanconi Anemia Complementary Group A (FANCA) Facilitates the Occurrence and
Progression of Liver Hepatocellular Carcinoma.
Dig Dis Sci. 2024 Jan 28. doi: 10.1007/s10620-024-08282.
PubMed
Abstract available
Prognosis prediction and risk stratification of transarterial chemoembolization
or intraarterial chemotherapy for unresectable hepatocellular carcinoma based on
machine learning.
Eur Radiol. 2024 Jan 30. doi: 10.1007/s00330-024-10581.
PubMed
Abstract available
Publisher Correction: Reclassification of therapeutic response of unresectable
hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha
RECIST.
Eur Radiol. 2024 Jan 29. doi: 10.1007/s00330-023-10575.
PubMed
2 AM in the Intensive Care Unit: What Could Go Wrong?
Gastroenterology. 2024;166:e13-e15.
PubMed
Nonalcoholic Fatty Liver Disease Gets Renamed as Metabolic Dysfunction-Associated
Steatotic Liver Disease: Progress But With Challenges.
Gastroenterology. 2024;166:229-234.
PubMed
Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid
accumulation and hyperlipidemia.
Hepatology. 2024 Jan 29. doi: 10.1097/HEP.0000000000000730.
PubMed
Comparison of six hepatocellular carcinoma prediction models in Japanese patients
after sustained virologic response undergoing rigorous surveillance for
hepatocellular carcinoma.
J Gastroenterol Hepatol. 2024 Jan 30. doi: 10.1111/jgh.16494.
PubMed
Abstract available
Reply to "The impact of infections on the onset of contrast-associated acute
kidney injury in patients with cirrhosis".
J Hepatol. 2024 Jan 31:S0168-8278(24)00102-8. doi: 10.1016/j.jhep.2024.
PubMed
An in-depth exploration of new clinical and prognostic characteristics of
decompensated liver cirrhosis patterns.
J Hepatol. 2024 Jan 31:S0168-8278(24)00104-1. doi: 10.1016/j.jhep.2024.
PubMed
A new era for steatotic liver disease: Evaluating the novel nomenclature in the
UK Biobank.
J Hepatol. 2024;80:e58-e60.
PubMed
Are there all-cause mortality differences between metabolic
dysfunction-associated steatotic liver disease subtypes?
J Hepatol. 2024;80:e53-e54.
PubMed
Can we use old NAFLD data under the new MASLD definition?
J Hepatol. 2024;80:e54-e56.
PubMed
Confirmatory biomarker diagnostic studies are not needed when transitioning from
NAFLD to MASLD.
J Hepatol. 2024;80:e51-e52.
PubMed
Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is
better than MAFLD criteria for lean patients with NAFLD.
J Hepatol. 2024;80:e61-e62.
PubMed
Sample types and patient preparation required when adopting the new fatty liver
disease nomenclature.
J Hepatol. 2024;80:e60-e61.
PubMed
What's in a name? New nomenclature for steatotic liver disease - to be or not to
be?
J Hepatol. 2024;80:e56-e58.
PubMed
Sex differences in prevalence and prognosis of steatotic liver disease
phenotypes: Biological sex matters.
J Hepatol. 2024;80:e68-e69.
PubMed
Steatotic liver disease as a new nomenclature for NAFLD from the perspectives of
the MENA region: One size fits all this time.
J Hepatol. 2024;80:e66-e68.
PubMed
Prevalence of steatotic liver disease and associated fibrosis in the United
States: Results from NHANES 2017-March 2020.
J Hepatol. 2024;80:e70-e71.
PubMed
Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors
in a large Brazilian cohort.
J Hepatol. 2024;80:e72-e74.
PubMed
A rare cause of liver fibrosis in an adult patient.
J Hepatol. 2024;80:e48-e50.
PubMed
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD.
J Hepatol. 2024;80:362-377.
PubMed
Abstract available
Inhibition of the Renal Apical Sodium Dependent Bile Acid Transporter Prevents
Cholemic Nephropathy in Mice with Obstructive Cholestasis.
J Hepatol. 2023 Nov 6:S0168-8278(23)05235-2. doi: 10.1016/j.jhep.2023.
PubMed
Abstract available
MASLD screening and diagnostic algorithms are interchangeable with existing NAFLD
literature.
J Hepatol. 2024;80:e89-e91.
PubMed
MASLD vs. NAFLD: A better definition for children with obesity at higher risk of
kidney damage.
J Hepatol. 2024;80:e87-e89.
PubMed
Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
J Hepatol. 2024;80:282-292.
PubMed
Abstract available
Changing from NAFLD to MASLD: The new definition can more accurately identify
individuals at higher risk for diabetes.
J Hepatol. 2024;80:e85-e87.
PubMed
Metabolic dysfunction-associated steatotic liver disease: Where does
non-alcoholic fatty liver disease in liver transplant recipients fit in this new
definition?
J Hepatol. 2023 Sep 15:S0168-8278(23)05098-5. doi: 10.1016/j.jhep.2023.
PubMed
Metabolic dysfunction-associated steatotic liver disease and
all-cause/cause-specific mortality among adults in the United States.
J Hepatol. 2024;80:e79-e81.
PubMed
Nutrients associated with metabolic dysfunction-associated steatotic liver
disease.
J Hepatol. 2024;80:e81-e82.
PubMed
Clinical and histological features under different nomenclatures of fatty liver
disease: NAFLD, MAFLD, MASLD and MetALD.
J Hepatol. 2024;80:e64-e66.
PubMed
Is the change from NAFLD to MASLD driven by political correctness?
J Hepatol. 2024;80:e74-e76.
PubMed
99% of patients with NAFLD meet MASLD criteria and natural history is therefore
identical.
J Hepatol. 2024;80:e76-e77.
PubMed
Food Insecurity and Pediatric Nonalcoholic Fatty Liver Disease Severity.
J Pediatr. 2024;265:113818.
PubMed
Abstract available
Comparative efficacy of terlipressin and norepinephrine for treatment of
hepatorenal syndrome-acute kidney injury: A systematic review and meta-analysis.
PLoS One. 2024;19:e0296690.
PubMed
Abstract available
Time-restricted feeding has a limited effect on hepatic lipid accumulation,
inflammation and fibrosis in a choline-deficient high-fat diet-induced murine
NASH model.
PLoS One. 2024;19:e0296950.
PubMed
Abstract available
The ubiquitin E3 ligase BFAR promotes degradation of PNPLA3.
Proc Natl Acad Sci U S A. 2024;121:e2312291121.
PubMed
Abstract available
Thank you for your interest in scientific medicine.